ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended September 30, 2014 – the first quarter of the Company’s 2015 fiscal year. ImmunoGen also provided an update on product programs and reiterated its guidance for its 2015 fiscal year.

Help employers find you! Check out all the jobs and post your resume.